Current Headlines

  1. TCS Launches 'Connected Clinical Trials' Platform On Its Advanced Drug Development Suite

    Tata Consultancy Services (TCS), (BSE: 532540, NSE: TCS) a leading global IT services, consulting and business solutions organization, has launched Connected Clinical Trials (CCT), an innovative Software as a Service (SaaS) platform that enables pharmaceutical companies to significantly transform patient engagement in clinical trials and improve the efficiency and accountability of the clinical supply process

  2. M3 Biotechnology Launches Clinical Trials For Alzheimer’s Disease Drug Focused On Restoring Lost Connections In The Brain

    A six-year-old biotech company at the leading edge of regenerative medicine is bringing a therapy for Alzheimer’s to Phase I clinical trials that is expected to slow or stop disease progression as indicated by pre-clinical studies, announced M3 CEO Leen Kawas

  3. PharmaCyte Biotech Research Identifies Enzyme Activity For Cannabinoid-Based Therapy To Fight Cancer

    PharmaCyte Biotech, Inc., a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, recently announced that its research partner, the University of Northern Colorado (UNC), has identified an organism whose genome contains the genetic code for production of an enzyme capable of activating a cannabinoid prodrug into its active cancer-killing form

  4. Takeda And HemoShear Therapeutics Enter Into Exclusive Drug Discovery Partnership In Liver Diseases

    Takeda Pharmaceutical Company Limited and HemoShear Therapeutics, LLC, a privately held biotechnology company, recently announced a partnership to discover and develop novel therapeutics for liver diseases, including nonalcoholic steatohepatitis (NASH)

  5. ImmunoGen Announces Investigational New Drug Application For IMGN632 For Hematological Malignancies Is Active

    ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, recently announced that the U.S. Food and Drug Administration (FDA) has completed the safety review of its investigational new drug (IND) application for IMGN632 in patients with CD123-positive hematological malignancies, including acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN)

  6. FDA Accepts New Drug Application For Methylene Blue MMX And Sets PDUFA Date For May 21, 2018

    Aries Pharmaceuticals, Inc. (Aries), a specialty pharmaceutical company commercializing best-in-class gastroenterology products, recently announced that the U.S. Food and Drug Administration (FDA) has set a PDUFA date of May 21st, 2018, for its decision on the New Drug Application (NDA) for Methylene Blue MMX (MB MMX)

  7. Exelixis Announces U.S. FDA Grants Priority Review For CABOMETYX (Cabozantinib) As A Treatment For Previously Untreated Advanced Renal Cell Carcinoma

    Exelixis, Inc. recently announced that the U.S. Food and Drug Administration (FDA) has determined the company’s supplemental New Drug Application (sNDA) for CABOMETYX (cabozantinib) for patients with previously untreated advanced renal cell carcinoma (RCC) to be sufficiently complete to permit a substantive review

  8. Regen BioPharma, Inc. Researchers Capitalize On Key Structure In Compounds That Activate Checkpoint NR2F6 For The Potential Treatment Of Autoimmune Diseases

    Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) believes it has taken full advantage of its recent prior discovery in developing small molecule drugs that activate NR2F6

  9. Amgen And Boston Children's Hospital Enter A Collaboration To Find New Genes And Drug Targets For Severe Pain Syndromes

    Amgen (NASDAQ: AMGN) and Boston Children's Hospital today announced that they have entered into a neuroscience research collaboration aimed at identifying novel pain targets based on human genetic analyses

  10. Cognition Therapeutics Receives Fast Track Designation From U.S. FDA For First-In-Class Alzheimer’s Candidate, CT1812

    Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational drug CT1812 for the treatment of patients with Alzheimer’s disease